A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.~Participants enrolled in Cohort A will be randomized to receive namilumab, or placebo, and will also be treated with a daily dose of prednisone or equivalent, in addition to any other background Immunosuppressive therapy (IST) currently prescribed. Namilumab or placebo will be administered subcutaneously (SC) every 4 weeks through Week 30 after the initial dosing period.~Participants enrolled in Cohort B will be administered namilumab SC in an open-label fashion, and must continue their background therapy without change to any ongoing oral corticosteroid dose or ISTs.~Further details are in the protocol.
A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.